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Background: Little is known about the burden of diabetes mellitus (DM) in pregnancy in low- and middle-
income countries despite high prevalence and mortality rates being observed in these countries.
Objective: To investigate the prevalence and geographical patterns of DM in pregnancy up to 1 year post-
delivery in low- and middle-income countries.
Search strategy: Medline, Embase, Cochrane (Central), Cinahl and CAB databases were searched with no
date restrictions.
Selection criteria: Articles assessing the prevalence of gestational diabetes mellitus (GDM), and types 1 and 2
DM were sought.
Data collection and analysis: Articles were independently screened by at least two reviewers. Forest plots were
used to present prevalence rates and linear trends calculated by linear regression where appropriate.
Main results: A total of 45 articles were included. The prevalence of GDM varied. Diagnosis was made by
the American Diabetes Association criteria (1.5015.5%), the Australian Diabetes in Pregnancy Society
criteria (20.8%), the Diabetes in Pregnancy Study Group India criteria (13.4%), the European Association for
the Study of Diabetes criteria (1.6%), the International Association of Diabetes and Pregnancy Study Groups
criteria (8.920.4%), the National Diabetes Data Group criteria (0.566.30%) and the World Health
Organization criteria (0.424.3%). Vietnam, India and Cuba had the highest prevalence rates. Types 1 and
2 DM were less often reported. Reports of maternal mortality due to DM were not found. No geographical
patterns of the prevalence of GDM could be confirmed but data from Africa is particularly limited.
Conclusion: Existing published data are insufficient to build a clear picture of the burden and distribution of
DM in pregnancy in low- and middle-income countries. Consensus on a common diagnostic criterion for
GDM is needed. Type 1 and 2 DM in pregnancy and postpartum DM are other neglected areas.
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D
iabetes mellitus (DM) is a metabolic disorder
resulting from a defect in insulin production,
impaired insulin action or both. It is one of the
major non-communicable diseases on the rise worldwide,
causing 4.8 million deaths and morbidity in 371 million
people every year (1). In recent years, patterns of change
have been observed in the age of onset of DM with
younger populations now disproportionately affected. It
is currently estimated that 28 million women of repro-
ductive age suffer from DM worldwide (2). Majority of
these women have type 2 DM, and 80% of the burden is
found in low- and middle-income countries (2).
In pregnancy, DM can either be pre-existing (type 1 or
2) or gestational diabetes mellitus (GDM). In pre-existing
DM, risk factors such as genetic predisposition, family
history of type 1 DM and autoimmune disorders are
crucial in the development of type 1 DM (3, 4). Factors
which play a significant role in both type 2 DM and
GDM include obesity, unhealthy diets, physical inactivity,
family histories of type 2 DM, maternal age and ethnicity
(4, 5). Other lifestyle changes such as alcohol abuse and
smoking have also been implicated in the aetiology of
type 2 DM (6).
A diabetic pregnant woman and her unborn child are
at increased risk of pregnancy complications such as
pre-eclampsia, infections, obstructed labour, postpartum
haemorrhage, preterm births, stillbirths, macrosomia,
miscarriage, intrauterine growth retardation, congenital
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anomalies, birth injuries and death in worst case scenarios
(7, 8). Women are also at risk of long-term diabetic compli-
cations, including retinopathy, nephropathy and neuropathy.
Beyond the 42-day postpartum period, consequent
effects of DM in pregnancy can also be seen. An estimated
3050% of women with a previous history of GDM
develop it again in subsequent pregnancies, and within
510 years, 50% of these women will develop type 2 DM
(911). In addition, babies born from diabetic pregnancies
have an increased risk of developing obesity in childhood,
metabolic disturbances in adolescence and type 2 DM
in adulthood, linked to the metabolic imbalance experi-
enced in utero (3).
Appropriate diagnosis, care and management of DM
in the pre-pregnancy, pregnancy and post-pregnancy
periods are important to minimise the risk of compli-
cations, long-term effects or catastrophic death of the
mother and/or baby (12). Several diagnosing criteria for
GDM are used worldwide. These include the ADA
(America Diabetes Association), ADIPS (Australian Dia-
betes in Pregnancy Society), DIPSI (Diabetes in Preg-
nancy Study Group India), EASD (European Association
for the Study of Diabetes), IADPSG (International
Association of Diabetes and Pregnancy Study Groups),
NICE (National Institute of Health and Clinical Excel-
lence), NDDG (National Diabetes Data Group), SIGN
(Scottish International Guidelines Network) and WHO
(World Health Organization for both pregnant and non-
pregnant populations) (13, 14). These criteria differ in
the group screened (universal or only high-risk women),
gestational age at screening, loading dose for the oral
glucose tolerance test (OGTT) and the OGTT cut-off
levels of plasma glucose.
In some of the poorest areas of the world, diffi-
culties in accessing and receiving both maternity and
general medical care increase the risks pregnant women
face from the complications of diabetes in pregnancy.
It is estimated that women with type 1 DM face a 520%
risk of dying in pregnancy compared to non-diabetic
pregnant women if adequate care is not provided (15).
Despite the high burden of diabetes in low- and
middle-income countries, little is known about the con-
tribution of DM in pregnancy in these countries. This
review aims to investigate the prevalence and geo-
graphical pattern of DM (pre-existing and gestational)
in pregnancy and up to 1 year post-delivery in low- and
middle-income countries. We took 1 year as the cut-off
point because it is up to this period that late maternal
deaths are recorded (worldwide) and is also jointly agreed
by the WHO, UNFPA, UNICEF and the World Bank (16).
Methods
A priori protocol was written before undertaking the
review and the PRISMA statement used to guide reporting
(17).
Inclusion and exclusion criteria
Randomised, non-randomised and observational study
designs of primary or secondary studies were eligible for
inclusion if they reported on prevalence and/or mortality
rates due to any type of DM in pregnancy up to 1 year after
childbirth. Editorials, letters, commentaries and short
notes were excluded. Systematic reviews were not eligible
for inclusion; however, their references were screened for
relevant primary or secondary studies. We also excluded
studies that had modelled or extrapolated prevalence or
mortality estimates.
Studies that looked at pregnant women with pre-
existing DM (type 1 and 2) or GDM confirmed by any
international diagnostic criteria, for example, the ADA,
ADIPS, DIPSI, EASD, IADPSG, NDDG, NICE, SIGN
and WHO, were included. Studies with women up to 1
year since their last delivery with confirmed diagnosis
of diabetes were also eligible for inclusion. Studies re-
garding non-diabetic pregnant women, diabetic women
who had delivered more than 1 year ago and self-reported
diabetic women with no clinical and diagnostic confir-
matory tests were excluded.
Prevalence of GDM and DM (type 1 and 2) in
pregnancy up to 1 year post-delivery was the primary
outcome measure. Mortality due to GDM and DM
(type 1 and 2) in pregnancy up to 1 year post-delivery
was the secondary outcome measure; screening criteria,
gestational age, parity, maternal age and setting were
included as explanatory outcome measures. Prevalence
or mortality related to impaired glucose tolerance (IGT)
and metabolic syndrome were excluded. All studies which
were carried out in countries listed by the World Bank
as low, lower and upper middle-income countries were
considered for inclusion (18).
Electronic searches
A comprehensive search of Medline, Medline-in-process,
Embase, CAB abstracts, Cochrane Central Register of
Controlled Trials and Cinahl databases was conducted
using appropriate MeSH terms combined by Boolean
commands ‘AND’ and ‘OR’. Key words in the search
strategy included (diabetes OR type 1 diabetes OR juvenile
diabetes OR child diabetes OR autoimmune diabetes OR
insulin-dependent diabetes OR DM OR type 2 diabetes
OR adult onset diabetes OR non-insulin-dependent dia-
betes OR gestational diabetes) AND (maternal mortality
OR maternal morbidity OR pregnancy OR pregnant
women OR pregnancy complications) AND (developing
countries OR low-income countries OR lower income
countries OR low- and middle-income countries OR
upper middle-income countries). Reference lists of in-
cluded studies and review papers were screened for
relevance and hand searching of relevant reports done.
Although the Cochrane collaborative strongly advises
against setting language restrictions to prevent effects of
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possible language bias by exclusion of articles (and study
populations) published in non-English journals, articles
in the English language were the only ones eligible for
inclusion due to financial constraints tied to translation
costs of the non-English papers. There were no date
restrictions and all the searches ran until March 2014.
Data management and extraction
Reference Manager (version 12) was used to manage
all of the citations retrieved. Two reviewers (LK, NB)
initially screened titles and abstracts independently using
the inclusionexclusion criteria. Relevant articles were
selected and their full texts sought. These were then
screened for eligibility by all of the reviewers (LK, NB,
JH and JB) independently, ensuring at least two reviewers
screened each article. Where disagreements arose about
inclusion of an article, discussions resolved these. A data
extraction form was developed incorporating important
characteristics such as study design, country, sampling
frame, sample size and relevant outcomes.
Data synthesis and analysis
Table 1 and 2 were used to summarise characteristics of
the included studies: one showing a general methodolo-
gical description of the studies and the second show-
ing outcome measures of interest. Prevalence of GDM
and type 1 and 2 DM were computed. 95% confidence
intervals of GDM prevalence were calculated and com-
piled (Fig. 2) using metadata viewer for epidemiological
studies (version 1, March 2011). The overall prevalence
results could not be pooled together by a meta-analysis
due to underlying clinical heterogeneity such as differ-
ences in the gestational age for screening, maternal age
and different criteria used which were all likely to
influence the results and also lack of a comparator group
for most studies. As part of the exploration of geogra-
phical patterns of prevalence, the (rural or urban) setting
of the study was identified. Association between GDM
and gross national income (GNI) per capita (19) was
determined using a linear regression model and a scatter
plot was used to illustrate findings (Fig. 3).
Risk of bias
The studies included were assessed for risk of bias by
two reviewers independently (LK, NB). The validity of
methodology, its appropriateness and reporting of results
were assessed (20, 21). Seven criteria were used to assess
three risks of biases, namely measurement bias, selection
bias and attrition bias.
Results
The searches conducted yielded 1,836 citations. After
screening titles, abstracts and full texts, 45 studies (Fig. 1)
with 281,661 participants were included. Among the
excluded studies were eight non-English articles, with
two each in German and French, and one each in
Norwegian, Spanish, Persian and Portuguese after ab-
stract and title screening.
Characteristics of included studies
The included studies were from Pakistan (2224), India
(2537), Sri Lanka (38, 39), Bangladesh (40), Thailand
(4145), China (4649), Vietnam (50, 51), Turkey (52
56), Iran (5759), South Africa (60), Ethiopia (61),
Nigeria (6264), Argentina (65), Brazil (66) and Cuba
(67) (Table 1). The largest number of studies (12) came
from India. The studies included were either cohort
or cross-sectional studies. About 60% of the studies (26
studies) were based in urban areas. Two studies from
Bangladesh and Ethiopia specified a rural population
base. Three other studies reported that both urban and
rural areas were covered, while in 14 studies, the setting
was not described. In Fig. 2, the included studies are
grouped into 33 studies which were facility-based and 12
which were population-based (also seen Table 1). Facility-
based studies were considered as those sampling one
or a few hospitals/clinics, and were not reported to be
representative of the total targeted population in the
study district/region. Population-based studies included
those that reported to have sampled the whole popula-
tion of interest in the selected district(s)/region or those
which reported systematic sampling of the population
in a region/district likely to be representative of the total
targeted population (Table 1, sampling frame). Sample
sizes across all the studies included varied from as low
as 172 to 105,472 participants.
Table 2 shows outcome measures of interest across
the various studies. In general, studies varied from
reporting on prevalence only to reporting on prevalence,
risk factors, pregnancy outcomes and interventions (data
not shown). Fifteen studies reported on prevalence only
(24, 25, 2831, 34, 35, 37, 49, 53, 60, 61, 66, 67), 10
studies on prevalence and risk factors only (38, 40, 41, 46,
47, 50, 52, 54, 57, 62), 12 studies on prevalence, risk
factors and pregnancy outcomes/obstetric complications
(21, 25, 26, 35, 4144, 54, 57, 6264), and eight studies
on prevalence, pregnancy outcomes/complications and
some form of intervention (22, 31, 32, 38, 47, 50, 58, 59).
The interventions in the latter group included diet/
medical nutrition therapy only, insulin only or combined
diet and insulin therapy.
Maternal age ranged from as low as 13 years in
Argentina to 54 years of age in Nigeria (Table 2). Parity
was poorly reported by only 10 studies. Among these,
GDM prevalence was higher in women who had given
birth to one child or more, than in those giving birth
for the first time (Table 2). Gestational age at diagnosis
of GDM was only reported by about 60% of the studies
included. The majority of these studies reported on
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Table 1. Description of included studies
Author, year Country Study design Setting Sampling frame Sample size
1. Akter et al. (1996) Pakistan Retrospective cohort Unclear Tertiary hospital 6,830
2. Jawad et al. (1996) Pakistan Prospective cohort Unclear Tertiary hospital 5,559
3. Khan et al. (1991) Pakistan Prospective cohort Unclear Tertiary hospital 1,267
4. Ramachandran et al. (1994) India Cross sectional Unclear 2 gynaecology centres 950
5. Ramachandran et al. (1998) India Prospective cohort Urban 2prenatal clinics 1,036
6. Grewal et al. (2012) India Prospective cohort Urban Tertiary hospital 298
7. Hill et al. (2005) India Prospective cohort Urban Tertiary hospital 785
8. Swami et al. (2008) India Prospective cohort Unclear Secondary/ tertiary hospital 1,225
9. Seshiah et al. (2012) India Prospective cohort Unclear Community health centres 1,463
10. Seshiah et al. (2004) India Prospective cohort Unclear Tertiary hospital 1,251
11. Tripathi et al. (2012) India Prospective cohort Urban Tertiary hospital 687
12. Wahi et al. (2011) India Prospective cohort Unclear Tertiary hospital 2,025
13. Siribaddana et al. (1998) Sri Lanka Prospective cohort Unclear Secondary/ Tertiary hospital 721
14. Boriboonhirunsarn et al. (2004) Thailand Cross sectional Urban Tertiary hospital 1,200
15. Chanprapaph et al (2004) Thailand Retrospective cohort Urban Tertiary hospital 1,000
16. Lueprasitsakul et al. (2008) Thailand Retrospective cohort Urban Tertiary hospital 637
17. Serirat, S. et al. (1991) Thailand Prospective cohort Urban Secondary/ tertiary hospital 25,997 Facility-based studies
18. Sumeksri et al. (2006) Thailand Prospective cohort Urban Secondary/ Tertiary hospital 1,332
19. Fan et al. (2006) China Prospective cohort Urban Tertiary hospital 20,512
20. Tran et al. (2013) Vietnam Prospective cohort Urban Tertiary hospital 2,772
21. Hirst et al. (2012) Vietnam Prospective cohort Urban Tertiary hospitals 2,702
22. Baci et al. (2013) Turkey Prospective cohort Urban Tertiary hospital 614
23. Karcaaltincaba et al. (2009) Turkey Retrospective cohort Urban Tertiary hospital 21,531
24. Kosus et al. (2012) Turkey Retrospective cohort Urban Tertiary hospital 808
25. Erem et al. (2002) Turkey Cross sectional Unclear 7 health stations 807
26. Tanir et al. (2005) Turkey Retrospective cohort Urban Tertiary hospital 3,548
27. Hadaegh et al. (2005) Iran Prospective cohort Unclear Obstetric clinics in Bandar Abbas city 800
28. Hossein-Nezhad et al. (2006) Iran Cross sectional Urban 5 teaching hospitals 2,416
29. Keshavarz et al. (2005) Iran Prospective cohort Urban Tertiary hospital 1,310
30. Ranchod, H.A. et al. (1991) South Africa Prospective cohort Urban Tertiary hospital 1,721
31. Anzaku and Musa (2013) Nigeria Cross sectional Urban Tertiary hospital 253
32. Olarinoye et al. (2004) Nigeria Prospective cohort Urban Tertiary hospital 293
33. Ozumba et al. (2004) Nigeria Retrospective cohort Urban Tertiary hospital 12,030
34. Balaji et al. (2012) India Cross sectional Urban, suburban
& rural
Community health centres 819
35. Seshiah et al. (2008), (2009) India Cross sectional Urban, suburban
& rural
20 health posts, 10 primary & community
centres
12,056
36. Zargar et al. (2004) India Prospective cohort Urban & rural All ANC in 6 districts of Kashmiri valley 2,000
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a diagnosis being made between the 24th and 32nd
gestational weeks.
The screening criteria used were reported by all the
studies included. Thirty-nine studies used universal
screening of participants while the remaining six studies
used selective screening of pregnant women at high risk
of GDM (Table 2), except those with multiple pregnan-
cies and other predisposing medical conditions. The
most common diagnosing criteria used were the WHO
criteria, followed by the NDDG criteria, and then the
ADA criteria. The IADPSG, ADIPS, DIPSI, EASD
and modified WHO criteria were less popular diagnos-
ing criteria. GDM was the most frequently documented
type of diabetes in pregnancy reported by all the studies,
while the prevalence of pre-existing type 1 or type 2 DM
was only reported in seven studies.
Prevalence
There were 58 observations of GDM prevalence from
the 45 studies, because more than one criterion was used
by some studies (Table 2). Prevalence using the ADA
criteria (15 observations) ranged from 1.50 to 15.50%.
With the NDDG criteria (16 observations), prevalence
ranged from 0.56 to 6.30%, the WHO criteria (19
observations) ranged from 0.4 to 24.30%, and the
IADPSG criteria (four observations) ranged from 8.9
to 20.4%. EASD, ADIPS, DIPSI and WHO modified
criteria each had only one observation with prevalence
of 1.56, 20.8, 13.4 and 17.25% reported, respectively.
GDM prevalence rates and their confidence intervals are
summarised in Fig. 2.
Prevalence of type 1 and 2 DM were reported as
ranging from 0.20 to 0.70%. Neither postpartum DM
after 6 weeks nor maternal mortality due to any type of
DM was reported.
The association between GDM and GNI per capita
is shown in Fig. 3. A significant negative correlation is
seen (B0.611; R0.358; p0.007). Three studies
(28, 50, 51) are clear outliers on the graph, and without
these the suggestion of an association is further reduced
(B0.314; R0.291; p0.042).
Risk of bias
A summary of the risk of bias in included studies is
shown in Fig. 4. The diagnostic criteria used were well
defined in all of the studies. A total of 86% (39 studies)
had clear case definitions, and 95% (43 studies) reported
clearly on the sampling design and recruitment processes
used. However, studies were subject to a high risk of bias
in a few parameters. Confidence intervals were only
reported by 26% (12 studies). Only 7% (three studies)
randomly sequenced the selection of participants and
31% (14 studies) reported on loss to follow-up.T
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Table 2. Characteristics of included studies (gestational diabetes mellitus, type 1 and 2 diabetes mellitus, postpartum type 2 diabetes mellitus)
Author, year Country
Maternal age
(years)
Parity
(GDM only)
Gestational age
at diagnosis
Diagnosing
criteria
Screening
criteria
(GDM only)
GDM
prevalence
(%)
Total DM
prevalence
(T1, T2)
Prevalence of
postpartum
type 2 DM
1. Akter et al. (1996) Pakistan Mean 26.9 Null19%
181%
Unclear WHO Selective 3.30 0.6% Not reported
2. Jawad et al. (1996) Pakistan 2045 Null21%
179%
Unclear NDDG Universal 3.45 Not reported Not reported
3. Khan et al. (1991) Pakistan 2234 Not reported B28 weeks &
2832 weeks
NDDG Universal 3.20 Not reported Not reported
4. Ramachandran et al. (1994) India B2035 Not reported Unclear NDDG Universal 0.56 0.6% Not reported
5. Ramachandran et al. (1998) India Unclear Not reported 2428 weeks NDDG Universal 0.86 0.29% Not reported
6. Grewal et al. (2012) India 1839 Not reported 1st trimester, &
2428 weeks
ADA Universal 15.49 Not reported Not reported
7. Hill et al. (2005) India 1640 Not reported 2832 weeks ADA Universal 5.80 Not reported Not reported
8. Swami et al. (2008) India 1840 Not reported NR ADA Universal 7.70 Not reported Not reported
9. Seshiah et al. (2012) India Mean 23.6
(93.32)
Not reported 2234 weeks DIPSI
IADPSG
Universal 13.4
14.6
Not reported Not reported
10. Seshiah et al. (2004) India 1927 Not reported Unclear WHO Universal 17.70 Not reported Not reported
11. Tripathi et al. (2012) India 2032 Unclear 2428 weeks ADA Universal 1.50 Not reported Not reported
12. Wahi et al. (2011) India 2230 Not reported 2428 weeks WHO Selective 6.94 Not reported Not reported
13. Siribaddana et al. (1998) Sri Lanka 1544 Not reported 2428 weeks WHO Universal 5.50 Not reported Not reported
14. Boriboonhirunsarn et al. (2004) Thailand 2536 Unclear 7.616.6 weeks NDDG Selective 5.10 Not reported Not reported
15. Chanprapaph et al. (2004) Thailand Mean 2133 Unclear Unclear NDDG Selective 2.90 0.2% Not reported
16. Lueprasitsakul et al. (2008) Thailand Unclear Not reported Unclear NDDG Selective 1.50 Not reported Not reported Facility-based
17. Serirat et al. (1991) Thailand 1541 Null43%
157%
Unclear NDDG Universal 2.02 Not reported Not reported studies
18. Sumeksri et al. (2006) Thailand 3034 Not reported 25.628 weeks NDDG Universal 2.40 Not reported Not reported
19. Fan et al. (2006) China 2635 Not reported Unclear NDDG Universal 3.80 Not reported Not reported
20. Tran et al. (2013) Vietnam 1644 Null36%
]164%
2432 weeks ADA
IADPSG
ADIPS
WHO
Selective 5.9
20.4
20.8
24.3
Not reported Not reported
21. Hirst et al. (2012) Vietnam 2235 Unclear 2432 weeks ADA
IADPSG
Universal 6.1
20.3
Not reported Not reported
22. Baci et al. (2013) Turkey 1845 Not reported 2428 weeks ADA Universal 1.95 Not reported Not reported
23. Karcaaltincaba et al. (2009) Turkey 1449 Not reported Unclear ADA
NDDG
Universal 4.48
3.17
Not reported Not reported
24. Kosus et al. (2012) Turkey Unclear Unclear 2428 weeks ADA
NDDG
Universal 8.1
5.6
Not reported Not reported
25. Erem et al. (2002) Turkey B2030 Unclear 2432 weeks NDDG Universal 1.23 Not reported Not reported
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Table 2 (Continued )
Author, year Country
Maternal age
(years)
Parity
(GDM only)
Gestational age
at diagnosis
Diagnosing
criteria
Screening
criteria
(GDM only)
GDM
prevalence
(%)
Total DM
prevalence
(T1, T2)
Prevalence of
postpartum
type 2 DM
26. Tanir et al. (2005) Turkey 27.337.9 Unclear Unclear ADA Universal 3.10 Not reported Not reported
27. Hadaegh et al. (2005) Iran 1930 Not reported Unclear ADA
NDDG
Universal 8.90
6.30
Not reported Not reported
28. Hossein-Nezhad et al. (2006) Iran 1545 Unclear Unclear ADA
NDDG
Universal 4.70
3.97
Not reported Not reported
29. Keshavarz et al. (2005) Iran 2035 Unclear 13.428.6 weeks ADA Universal 4.80 Not reported Not reported
30. Ranchod et al. (1991) South
Africa
Unclear Not reported Unclear EASD
WHO
Universal 1.56
3.78
0.23% Not reported
31. Anzaku and Musa (2013) Nigeria 2140 Unclear 2428 weeks WHO Universal 1.60 Not reported Not reported
32. Olarinoye et al. (2004) Nigeria 1841 Mean: 1.3 Unclear WHO
NDDG
Universal 6.45
2.02
Not reported Not reported
33. Ozumba et al. (2004) Nigeria 1554 0 to 481%
419%
Unclear WHO Universal 1.01 0.65% Not reported
34. Balaji et al. (2012) India Mean 23.8
(93.48)
Not reported 2428 weeks WHO Universal 10.5 Not reported Not reported
35. Seshiah et al. (2008), (2009) India 1927 Not reported 16.934.3 weeks WHO Universal 13.90 Not reported Not reported
36. Zargar et al. (2004) India 1838 Mean: 2.1 24 weeks ADA
WHO
Universal 3.10
4.40
Not reported Not reported
37. Dahanayaka et al. (2012) Sri Lanka 19]35 142.2%
2 to 455.8%
42.0%
2428 weeks WHO
IADPSG
Universal 7.16
8.89
Not reported Not reported
38. Sayeed et al. (2005) Bangladesh 1844 Not reported B26 & 26 weeks WHO Universal 8.20 Not reported Not reported
39. Yang et al. (2009) China 2030 Not reported Unclear ADA Universal 4.35 Not reported Not reported Population-
40. Yang et al. (2002) China 2628 Not reported 2630 weeks WHO Universal 1.84 Not reported Not reported based studies
41. Zhang et al. (2011) China B2535 Not reported 2630 weeks WHO Universal 4.90 Not reported Not reported
42. Seyoum et al. (1999) Ethiopia 2035 Unclear Unclear WHO Universal 3.70 Not reported Not reported
43. McCarthy et al. (2010) Argentina 1345 Unclear 2428 weeks WHO Universal 5.80 Not reported Not reported
44. Schmidt et al. (2000) Brazil 2233 Unclear 2128 weeks WHO Universal 0.40 Not reported Not reported
45. Davilla et al. (2011) Cuba Unclear Null14%
186%
B20 to32 weeks WHO
modified
Universal 17.25 0.70% Not reported
T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; GDM, gestational diabetes mellitus; DM, diabetes mellitus; WHO, World Health Organization; ADA, American Diabetes
Association, ADIPS, Australian Diabetes in Pregnancy Society; NDDG, National Diabetes Data Group; DIPSI, Diabetes in Pregnancy Study Group India; EASD, European Association for the
Study of Diabetes; IADPSG, International Association of Diabetes and Pregnancy Study Groups.
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Discussion
Our review is the first to systematically summarise the
published literature on prevalence of GDM and type 1
and 2 DM in pregnancy in low- and middle-income
countries. We found 45 studies recording the prevalence
of DM in pregnancy which passed our selection criteria.
They only cover a select number of countries and large
areas of Africa and Asia are not covered by existing
studies. GDM prevalence ranged from 0.40 to 24.3% and
pre-existing DM (type 1 and 2) ranged from 0 to 0.7%.
It is well known that a wide variation of DM is seen
across countries (68). High prevalence rates are reported to
occur among Asian, Latin America and Middle Eastern
populations. Ethnicity (69) and geographical variation
(70, 71) are important factors and are well documented
across high-income countries such as Bahrain (13.5%)
(72), Qatar (16.3%) (73), United Arab Emirates (14.2
23.1%) (74), Hong Kong (14.2%) (75), Ireland (9.4
12.4%) (76), Israel (6.07%) (77) and the United States
(210%) (78). In our study, the highest prevalence of GDM
was reported from Vietnam (50, 51), India (2830, 34, 35,
37) and Cuba (67), followed closely by Bangladesh (40)
and Iran (57). Although the prevalence ranges that we
found were wide, most were fairly consistent with
the global GDM prevalence ranging between 1 and 14%
(70), except those from Vietnam which were unusually
high. Although data is sparse, we also found one un-
expectedly high level of GDM prevalence reported in
Nigeria of 6.45%, which is comparable to the levels found
in some of the Asian countries with high ethnic predis-
position to DM. The comparative prevalence of DM in
Africa’s general population is 5.7% (19.8 million adults),
Fig. 1. Flow chart of study selection. In general, studies were excluded based on participants (if it included women who were not
pregnant or those beyond 1 year in the postpartum period), study design (if these were commentaries, letters of correspondence,
systematic reviews), outcome measure (if it did not include relevant outcomes sought) and was not a low- and middle-income
country as defined by the World Bank.
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which is the lowest in all the regions, and also lower
than the average global prevalence estimated at 8.3% (79).
Nonetheless, this finding from the study from Nigeria
was not corroborated by using different diagnostic criteria
(Table 2), and a comparison was not done on the same
population. The study was also facility-based and partici-
pants had been randomly allocated to either WHO
(75 g OGTT) or NDDG (100 g OGTT) study arms for
comparison (63). In general, facility-based studies have
higher GDM prevalence levels than population-based
studies due to increased likelihood of patients presenting
at health facilities. Hence, caution should be taken in the
interpretation of this result.
One of the major limitations our review highlights is
the difficulty in determining prevalence due to the lack
of consistency in the use of diagnosing criteria (e.g. ADA,
WHO, NDDG, IADPSG). The various diagnostic cri-
teria use different loading doses for OGTT and different
Fig. 2. DGM prevalence and confidence intervals (CI).
Fig. 3. Prevalence of gestational diabetes mellitus against gross national income per capita in thousands (US$).
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thresholds for fasting times (between 1 and 3 hours).
The number of abnormal plasma glucose values consid-
ered to be adequate for a diagnosis also change when
using the various criteria. For example, the ADA criteria
uses a loading dose of 100 g for OGTT, and allows
for two or more abnormal values for a diagnosis to be
made, whereas the WHO criteria recommends 75 g
for OGTT allowing only one or more abnormal values
to be used for diagnosis (13, 80). This is compounded
by the differences in sensitivity and specificity between
the diagnosing criteria. In an ideal setting, a clinical test
with the highest accuracy to identify patients with a
disease (sensitivity) and those without a disease (specifi-
city) is usually desirable. However, most clinical tests
do not always satisfy this ideal. A systematic review by
Donovan et al. investigated the sensitivity and specificity
of the various tests for diagnosing GDM using different
thresholds (81). The authors found that at the thres-
hold of 7.8 mmol/L, the ADA criteria had the highest
sensitivity of 88 (8697)%, followed by NDDG criteria at
85 (7392)% then the WHO criteria at 70 (4385)%.
IADPSG had very low sensitivity at 12 (718)%. Con-
versely, the IADPSG had the highest specificity at 97
(9598)%, compared to that of the WHO, ADA and
NDDG criteria at 89 (7394)%, 84 (7987)% and 83 (78
87)%, respectively. To date, there is still a lack of clarity
as to which diagnostic criteria should be used. The
various debates are centred around frequency of diag-
nosis by different criteria, cost effectiveness and the
dilemma of undiagnosed cases who are at risk of poor
maternal and perinatal outcomes if they remain unde-
tected, and where care may be sub-optimal (82, 83).
We considered the possibility of conducting meta-
analyses in this review but did not do these as there is
expected to be considerable variability across ethnic
groups and countries. Pooling of data even from a single
country was not done due to the variation in use of
diagnostic criteria and lack of a control group for most
studies.
Pre-existing (type 1 and 2) DM in pregnancy was
reported by very few studies. Since the highest burden of
type 2 DM exists in low- and middle-income countries
also affects women of reproductive age (2), it is surprising
that studies did not capture these women while pregnant.
A number of the studies in our review did however
specifically exclude women with pre-existing diabetes.
No studies reported on postpartum type 2 diabetes (after
6 weeks) indicating an acute lack of information on
women followed up to 1 year after childbirth. This could
be linked to poor postnatal attendance and resource
constraints in health services (84, 85). There were no
studies reporting on maternal deaths due to diabetes.
These could be due to several reasons such as deaths
being masked by misclassification or inappropriate cod-
ing or missed because they were late maternal deaths
that occurred within 1 year after delivery. Undiagnosed
diabetes may also be another contributing factor. Up to
50% of people living with diabetes worldwide are
currently undiagnosed (1), and it is known that diabetes
can lead to complications in pregnancy such as preg-
nancy-induced hypertension, pre-eclampsia, postpartum
haemorrhage and increased risk of infections. It is
possible that in undiagnosed diabetic patients who
develop complications in pregnancy and succumb to it,
these complications could have been attributed as the
main cause of death and not diabetes which was the
underlying cause of death.
A statistically significant inverse relationship was seen
between the prevalence of GDM and a country’s wealth
as measured by the GNI. It was expected that with
increasing wealth GDM would become more prevalent,
and/or the functionality of the health system would
Lost to follow up (attrition bias)
Random sequence generation (selection bias)
Sampling design/recruitment (selection bias)
Description of population characteristics (selection bias)
Confidence intervals (measurement bias)
Defined criteria for diagnosis (measurement bias)
Case definition (measurement bias)
0% 20% 40% 60% 80% 100%
Proportion of studies
Low risk of bias high risk of bias Unclear risk of bias Not applicable
Fig. 4. Risk of bias summary (bias considerations vs. proportion of studies).
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improve, thus increasing the number of cases picked up
through screening. Although conclusions from this rather
crude analysis cannot be drawn, the trends observed
would be worth investigating further to understand and
plan for future health needs in countries with transition-
ing economies.
A number of limitations are inherent in our review
design. We were unable to assess papers in languages
other than the English language. Of the eight full-text
papers excluded for this reason, these included papers
in German (2), French (2), Norwegian (1), Spanish (1),
Persian (1), and Portuguese (1) languages. The likelihood
is that studies from Latin America, French-speaking
African countries and the Middle East are most likely
to be underrepresented if published in regional/local non-
English journals. We did not restrict the dates for our
search, and the majority of the studies were from the last
15 years. A few studies dated to the early 1990s and the
observed demographic changes in tendency to develop
DM in young adults could have affected any patterns we
might have observed. Studies included in this review
may have been subjected to some bias, primarily in the
form of selection bias. These were in terms of how
participants were selected (Fig. 4) and whether they were
representative of the target population as a whole which
may have affected the estimates of prevalence obtained.
Commonly, selection bias occurs when the participants
studied are not representative of the target population
about which conclusions are to be drawn. For example,
if an investigator wishes to estimate the prevalence of
disease X in adult residents of a certain town/city/region,
s/he may attempt to do this by selecting a random sample
from all the adults enrolled with several local health
facilities, and then recruit them. However, this design,
which is used in some studies included in this review,
would be systematically excluding participants who do
not access health facilities and therefore impact on the
results obtained. Eliminating selection bias in epidemio-
logical studies is therefore critical for accurate results
and should always be considered when defining a study
sample. In addition, including confidence intervals which
describe a range within which one can reasonably expect
the true value to lie would be important. Unfortunately,
this was not documented in a number of studies included
in this review.
Conclusion
DM is a growing public health problem in low- and
middle-income nations. This systematic review has high-
lighted the disparate and piecemeal data available from
the published literature on prevalence of DM during
pregnancy in these countries. Without such data, it will
be difficult to make rational decisions for allocating
precious funding within expanding health systems. A
global consensus on the diagnostic criteria for DM is
urgently required so that the public health burden of the
condition can be assessed. Studies of prevalence should
capture populations beyond those presenting in health
facilities, as little is known about undetected DM in
pregnancy. The current focus on GDM needs to be
extended to also capture diabetes in women of reproduc-
tive age especially just before pregnancy and in the
months after delivery, as these are the times when
interventions can optimise the health of women and
maximise the likelihood of a healthy foetus.
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